Testing the Safety of CB-5339 in Patients With Cancer
Phase 1 Withdrawn
Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study
Phase 1 Withdrawn
Erlotinib in Combination With Select Tyrosine Kinase Inhibitors in Adult Patients With Advanced Solid Tumors
Phase 1 Withdrawn
Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast Cancer
Phase 1 Withdrawn
A Clinical Trial to Evaluate Safety of Gusacitinib in Patients With Systemic Lupus Erythematosus (SLE) or Lupus
Phase 1 Withdrawn
Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations
Phase 1 Withdrawn
Phase I Evaluation of Immunotoxin LMB-100 Administered by Normothermic, Intrapleural Perfusion Following Cytoreductive Surgery in Participants With Pleural Mesotheliomas, or Pleural Effusions From Cancers Expressing Mesothelin
Phase 1 Withdrawn
Vaccine Response With NT-I7
Phase 1 Withdrawn
Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma
Phase 1 Withdrawn
Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and Lymphomas
Phase 1 Withdrawn
E7 TCR T Cell Immunotherapy for High-Grade Cervical Intraepithelial Neoplasia
Phase 1 Withdrawn
Tazemetostat in Treating Patients With Metastatic or Unresectable Solid Tumors or B-Cell Lymphomas With Liver Dysfunction
Phase 1 Withdrawn
In Vivo Persistence of Adoptively-Transferred TIL Cultured With Akti in People With Metastatic Melanoma
Phase 1 Withdrawn
A Phase I Study of Pazopanib as a Single Agent for Children With Refractory Solid Tumors
Phase 1 Withdrawn
RO4929097 in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia
Phase 1 Withdrawn
CT-011 and p53 Genetic Vaccine for Advanced Solid Tumors
Phase 1 Withdrawn
Wee1 Kinase Inhibitor AZD1775 and Combination Chemotherapy in Treating Children, Adolescents and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia
Phase 1 Withdrawn
Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
Phase 1 Withdrawn
BL22 Immunotoxin in Treating Patients With Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
Phase 1 Withdrawn
ONYX-015 With Cisplatin and Fluorouracil in Treating Patients With Advanced Head and Neck Cancer
Phase 1 Withdrawn
Soblidotin and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors
Phase 1 Withdrawn
Imetelstat for Children With Refractory or Recurrent Solid Tumors and Lymphoma
Phase 1 Withdrawn